Actelion (OTCMKTS:ALIOF) and Cyanotech (NASDAQ:CYAN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.
This table compares Actelion and Cyanotech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
13.6% of Cyanotech shares are owned by institutional investors. 24.5% of Cyanotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Actelion and Cyanotech’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Actelion||$2.46 billion||0.00||$707.04 million||N/A||N/A|
|Cyanotech||$34.12 million||0.53||$1.02 million||N/A||N/A|
Actelion has higher revenue and earnings than Cyanotech.
Volatility & Risk
Actelion has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Cyanotech has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
This is a summary of current ratings and target prices for Actelion and Cyanotech, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Actelion beats Cyanotech on 6 of the 8 factors compared between the two stocks.
Actelion Ltd. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of low molecular weight drugs. It specializes in the field of pulmonary arterial hypertension (PAH). It also specializes in human biology, especially in specific families of molecular targets, such as G-Protein Coupled Receptors. Its portfolio of PAH treatments covers the spectrum of disease, from World Health Organization (WHO) Functional Class (FC) II through to Functional Class (FC) IV, with oral, inhaled and intravenous medications. It also has treatments for a range of specialist diseases, including type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides type cutaneous T-cell lymphoma. Its products include Tracleer (bosentan), Opsumit (macitentan), Uptravi (selexipag), Ventavis (iloprost), Veletri (epoprostenol for injection), Zavesca (miglustat) and Valchlor (mechlorethamine) gel.
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. The company's products include Hawaiian BioAstin natural astaxanthin, a dietary antioxidant, which is used as a human nutraceutical and functional food ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye and joint health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. Cyanotech Corporation sells its products as packaged consumer products through distributors, retailers, and online channels, as well as directly to consumers; and in bulk quantities to manufacturers, formulators, and distributors. The company was founded in 1983 and is headquartered in Kailua-Kona, Hawaii.
Receive News & Ratings for Actelion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actelion and related companies with MarketBeat.com's FREE daily email newsletter.